Dopamine D-1 regulation of caudate neurotensin mRNA in the presence or absence of the nigrostriatal dopamine pathway.
Changes in extrapyramidal dopamine (DA) function significantly alter the activity of striatal neurotensin (NT) systems. Specifically, stimulation of DA D-1 or D-2 receptors increases or decreases striatal NT tissue levels, respectively. In contrast, removal of D-2 receptor basal activity with either an antagonist or lesion of the nigrostriatal DA projection increases striatal NT content. To understand better the significance of these changes in the levels of NT peptide, we determined the effects of treatment with the selective D-1 agonist, SKF 82958, alone or in combination with a lesion of the nigrostriatal DA pathway, on the levels of NT mRNA in various regions of the caudate nucleus. Removal of at least 90% of this DA pathway significantly increased NT mRNA in most, but not all, regions throughout the caudate nucleus. In contrast, four, but not one, administrations of SKF 82958 (2 mg kg-1 dose-1) increased NT mRNA levels in principally middle, but not rostral, caudate regions. Lesioning the nigrostriatal DA pathway enhanced the effects of SKF 82958 so that a lower, single dose (1 mg/kg) of this D-1 agonist also increased NT mRNA levels predominantly in the middle caudate sections. These findings demonstrate that DA D-1 receptors profoundly regulate the striatal expression of NT mRNA in a regionally selective fashion, which appears to be unique from that principally influenced by DA D-2 regulation.
Hanson
G R
GR
Department of Pharmacology and Toxicology, University of Utah, 112 Skaggs Hall, Salt Lake City, UT 84112, USA.
Keefe
K A
KA
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D002421:Caudate Nucleus / Q000737:chemistry* / Q000502:physiology; D004298:Dopamine / Q000032:analysis / Q000502:physiology; D018491:Dopamine Agonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D005116:Extrapyramidal Tracts / Q000737:chemistry / Q000502:physiology; D017403:In Situ Hybridization; D008297:Male; D009496:Neurotensin / Q000235:genetics*; D009714:Nucleus Accumbens / Q000737:chemistry / Q000502:physiology; D016627:Oxidopamine; D010300:Parkinson Disease / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000502:physiology*; D013378:Substantia Nigra / Q000502:physiology*; D013565:Sympatholytics
D001552:Benzazepines; D018491:Dopamine Agonists; D065127:Dopamine D2 Receptor Antagonists; D012333:RNA, Messenger; D017447:Receptors, Dopamine D1; D013565:Sympatholytics; D009496:Neurotensin; C071262:SK&F 82958; D016627:Oxidopamine; D004298:Dopamine